Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
La Oficina de Propiedad Intelectual de la Unión Europea cierra la solicitud de ayuda del Fondo para pymes (SME Fund) hasta la siguiente convocatoria en 2026.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
154
resultados
Última actualización
06/03/2026 [07:27:00]
Resumen de: AU2024345495A1
The disclosure pertains to treating a cognitive impairment, for example, an aging-associated cognitive impairment. In certain aspects, the disclosure describes methods of assaying a sample obtained from a subject having or suspected of having a cognitive impairment for one or more proteins selected from: DLL1, VNN2, VAV3, and SUMF1. In certain embodiments, the cognitive impairment is caused by a neurodegenerative disease, such as Alzheimer's disease. The methods further comprise identifying a subject as likely or not likely to respond positively to the plasma exchange therapy. In even further aspects, the disclosure describes methods for treating a cognitive impairment in the subject by a plasma exchange therapy, wherein based on the specific protein expression data, the subject is identified as likely or not likely to respond positively to the plasma exchange therapy. The plasma exchange therapy can be full and/or low volume plasma exchange. Also provided are kits suitable for performing the methods disclosed herein.
Resumen de: AU2026201203A1
Compounds described herein may be used for the treatment of neurodegenerative diseases linked to protein misfolding, including prion diseases, Alzheimers' disease, Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS), and also other neurodegenerative, degenerative, metabolic and ischemic conditions. Indeed, NAD metabolism impairment is also a critical feature in brain ischemia/reperfusion injury, Wallerian degeneration, kidney failure, multiple sclerosis, aging, and metabolic disorders such as diabetes mellitus. Therapies that elevate or stabilize NAD levels may thus have broad potential for treating many severely debilitating neurological and metabolic conditions. Evidence is provided herein with compounds from 8 lead series for NAD restoring properties and for therapeutic efficacy in cellular and/or animal models of prion disease, PD and ALS. eb e b
Resumen de: US20260061011A1
A Bifidobacterium animalis subsp. lactis for reducing Abeta42 deposition and an application, a name of the Bifidobacterium animalis subsp. lactis is Bifidobacterium animalis subsp. lactis IOB-LO7, and classified as Bifidobacterium animalis subsp. lactis, the Bifidobacterium animalis subsp. lactis IOB-LO7 is preserved in the General Microbiology Center of the China General Microbiological Culture Collection Center (CGMCC) on Dec. 23, 2021, with the collection number of CGMCC No. 24185. By reducing the levels of Aβ42 in the cerebral cortex and hippocampus, clearing Aβ amyloid plaques, improving communication between neurons, reducing brain neuroinflammation, and protecting nerve cells, it helps to restore cognitive function and improve Alzheimer's disease. Additionally, it can also improve gut microbiota imbalance caused by Alzheimer's disease.
Resumen de: AU2024325238A1
Material compositions and/or methods useful for the prophylaxis and/or treatment of protein depletion (proteinopenia) are provided, including material compositions that retains native function of a peptide/protein while limiting and/or preventing amyloid formation and/or aggregation of said peptide/protein. Material compositions and formulations for enhancing peptide/protein solubility, stability, circulation time, receptor interaction, brain penetrance, CSF half-life, facilitating peptide/protein synthesis and purification are also provided.
Resumen de: US20260062497A1
Provided are pharmaceutical formulations and dosing regimen for antibody-based treatment of amyotrophic lateral sclerosis (ALS).
Resumen de: AU2024327965A1
Material compositions and/or methods useful for the prophylaxis and/or treatment of a-syn protein depletion (proteinopenia) are provided, including material compositions that retain native function of a-syn protein while limiting and/or preventing amyloid formation and/or aggregation of said protein. Material compositions and formulations for enhancing protein solubility, stability, circulation time, receptor interaction, brain penetrance, CSF halflife, and for facilitating peptide/protein synthesis and purification are also provided.
Resumen de: EP4702978A1
An agent for treating or preventing amyotrophic lateral sclerosis, wherein an active component of the agent essentially consists of at least one selected from the group consisting of cycloserine, terizidone, and salts thereof. The active component may consist of at least one selected from the group consisting of cycloserine, terizidone, and salts thereof. The cycloserine may be D-cycloserine. The cycloserine may be L-cycloserine.
Resumen de: WO2026044269A1
Pharmaceutical compositions that include a benzimidazole, benzimidazole derivative, or a metabolite thereof and a selenium source, and their use in methods of treating, Alzheimer's disease, Parkinson's disease, frontotemporal lobe dementia, dementia, cognitive decline, neural injury, neurodegeneration, and/or a neurodegenerative and/or neuropsychiatric condition, a neurodegenerative and/or neuropsychiatric disease, and/or a neurodegenerative and/or neuropsychiatric disorder in a subject are described herein.
Resumen de: US20260053846A1
The disclosure provides polymeric compounds that inhibit binding of an amyloid-β-oligomer to cellular prior protein, methods for identifying such compounds, and their therapeutic use. In particular, the present disclosure provides a collection of anionic polymers and methods of using these compounds to treat amyloid-related disorders, e.g., Alzheimer's disease.
Resumen de: WO2026041069A1
Provided herein are pharmaceutical compositions comprising thermoresponsive polymer and uses thereof. Specifically, provided herein are pharmaceutical compositions comprising a mitochondrial uncoupler and a thermoresponsive polymer and uses thereof. Such pharmaceutical compositions can be useful for treating diseases, such as but not limited to NASH, overweight, obesity, medical complications related to overweight or obesity, type 2 diabetes (T2D), and Alzheimer's disease and related dementias (AD/ADRD).
Resumen de: WO2026044051A1
CD9 expressing microglia are observed in various human neurodegenerative diseases beyond traumatic brain injuries, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. CD9 blocking and FcγRIII blocking methods can be widely used as an intervention strategy to prevent disease-associated cognitive impairment. Therefore, disclosed herein are methods for treating a traumatic brain injury in a subject in need thereof that involve the step of administering to the subject a therapeutically effective amount of a composition comprising an anti-CD9 or an anti FcγRIII blocking agent, such as a blocking antibody.
Resumen de: US20260055090A1
Provided herein are compounds that selectively inhibit HDAC6, a protein whose activity is associated with a variety of diseases (e.g., cancer, neurological disorders). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating HDAC6-related diseases and disorders (e.g., Alzheimer's disease, cancer) with the compounds in a subject, by administering the compounds and/or compositions described herein.
Resumen de: US20260055402A1
Among other things, the present disclosure provides various oligonucleotide technologies including chirally controlled oligonucleotide compositions and technologies for manufacturing such oligonucleotide compositions. In some embodiments, a method is a method of treatment or prevention of Huntington's Disease in a subject in need thereof; a method of allele-specific knockdown of a mutant Huntingtin transcript in a subject; a method for delaying the onset of and/or reducing the severity of at least one symptom of Huntington's Disease in a subject with Huntington's Disease; a method of reducing the expression, level, amount and/or activity of a mutant Huntingtin gene or a gene product thereof; and/or a method of preparation of a medicament for treatment of Huntington's Disease, wherein the method pertains to the use of an oligonucleotide described herein, administered at a dose described herein. In some embodiments, the present disclosure provides doses, dosages, and formulations of an oligonucleotide described herein.
Resumen de: US20260055403A1
Methods for treating and/or preventing Alzheimer's disease via administration of thioredoxin-1 (Trx1) mRNA- or miR-551b miR-NA-containing exosomes derived from Flk-1+ vascular endothelial progenitor cells are reported. Further, wherein the subject carries the APOE E4 risk factor gene; wherein the subject also has mild cognitive impairment (MCI); and wherein the Flk-1+ exosomes are derived from vascular endothelial progenitor cells or the exosomes are derived from neural stem cells.
Resumen de: US20260053847A1
Provided is a drug for treating Alzheimer's disease, the drug enabling retention of cognitive function amelioration and nerve quality improvement for a specific time even after treatment ends. This drug for causal treatment of Alzheimer's disease (disease-modifying drug) contains hydrogen gas as an active ingredient.
Resumen de: US20260053792A1
Compounds having general formula I, a method for preparing same, a pharmaceutical composition thereof, and use thereof are provided. Specifically, a compound having a structure represented by general formula I, and a racemate, an R-isomer, an S-isomer and a pharmaceutically acceptable salt thereof, or a mixture thereof are provided. The compound promotes transcription factor EB (TFEB) nuclear translocation and lysosome generation, and can be used for preventing, treating, or assisting in treating various diseases related to lysosome dysfunction and biosynthesis insufficiency, especially neurodegenerative diseases caused by the accumulation of intracerebral pathological proteins (e.g., β-amyloid protein and α-synuclein), such as Alzheimer's disease (AD) and Parkinson's disease (PD).
Resumen de: US20260053782A1
A method of treating Parkinson's disease in a patient who is receiving N doses of levodopa per day to provide a total daily dose of X mg of levodopa and who is starting to experience motor fluctuations or starting to show signs of “wearing-off”, the treatment comprising administering more than N doses of levodopa per day to provide a total daily dose of X mg of levodopa and administering a single daily dose of Y mg of opicapone, wherein X is from 100 to 1000, N is from 2 to 10 and Y is from 25 to 50.
Resumen de: EP4700016A2
It is an object of the present invention to provide a novel pharmaceutical agent or method for treating ALS or suppressing the disease progress thereof, or treating symptoms caused by ALS or suppressing the disease progress thereof, wherein the agent can be administered particularly to patients obtaining high therapeutic effects, among ALS patients who require treatments. According to the present invention, there is provided a pharmaceutical agent for treating amyotrophic lateral sclerosis or suppressing the disease progress thereof or treating symptoms caused by amyotrophic lateral sclerosis or suppressing the disease progress thereof, which comprises, as an active ingredient, 3-methyl-1-phenyl-2-pyrazolin-5-one or a physiologically acceptable salt thereof, wherein the agent is administered by repeating a 14-day administration period and a 14-day drug holiday period, or by establishing an initial 14-day administration period and an initial 14-day drug holiday period and then repeating an administration period for 10 out of 14 days and a 14-day drug holiday period, and wherein a patient administered with the agent complies with specific criteria.
Resumen de: WO2026038861A1
The present invention relates to a novel chalcone derivative compound and a composition for the prevention or treatment of neurodegenerative diseases, comprising same as an active ingredient. The present invention can fundamentally eliminate the cause of neurotransmission dysfunction by simultaneously inhibiting the activities of two hyperactivated cholinesterases, unlike conventional symptomatic therapies that focus on the control of peripheral symptoms for various neurodegenerative diseases caused by a decrease in acetylcholine concentration, including Alzheimer's disease.
Resumen de: WO2026037392A1
The present invention provides a use of lactoferrin in combination with ergothioneine in the preparation of a drug for preventing and/or treating Alzheimer's disease. Compared with the use of lactoferrin or ergothioneine alone, in the present invention, the combined use of lactoferrin and ergothioneine at a specific ratio as an active pharmaceutical ingredient can reduce cell damage caused by Aβ25-35, reduce the expression of a p-Tau protein, lower the oxidative stress level and regulate apoptosis, alleviate memory impairment and cognitive dysfunction, and can reduce Aβ deposition in mouse plasma.
Resumen de: US20260048083A1
A method for treating Alzheimer's disease is disclosed. The method comprises identifying a subject and treating the subject with expanded natural killer cells (NKs). A composition for treating Alzheimer's disease is also disclosed.
Resumen de: US20260048058A1
The present disclosure relates to methods of treating Alzheimer's disease, diseases and/or conditions associated with Covid-19 infection, including long COVID, a post-acute infection syndrome, or symptoms of orthostatic intolerance comprising administration of a therapeutically-effective combination of a COX-2 inhibitor and an antiviral compound.
Resumen de: US20260048090A1
The present disclosure relates to an engineered M13 bacteriophage displaying amyloidogenic peptide motifs from amyloid beta 42 (Aβ42) at its surface. The present disclosure further relates to the use of the disclosed engineered M13 bacteriophage for detecting early species of Aβ, namely oligomeric and fibrillar Aβ, and preventing its aggregation promoting the inhibition of the progression of Alzheimer's disease and thus contributing to the treatment of this neurodegenerative disorder.
Resumen de: AU2024295008A1
The present invention recognizes that there is an unmet need for the treatment of mild cognitive impairment. A first aspect of the present invention generally relates to a method of treating, relieving, or alleviating mild cognitive impairment in a subject. A second aspect of the present invention generally relates to a method of treating, relieving, or alleviating Alzheimer's Disease in a subject. A third aspect of the present invention generally relates to a method of treating, relieving, or alleviating Alzheimer's Disease Psychosis in a subject. A fourth aspect of the present invention generally relates to a method of treating, relieving, or alleviating Alzheimer's Disease behaviors, aggression, agitation, anger, apathy, or a combination thereof, in a subject. A fifth aspect of the present invention generally relates to a method of treating, relieving, or alleviating Early Onset Alzheimer's Disease in a subject.
Nº publicación: AU2023455061A1 19/02/2026
Solicitante:
PRG S&TECH INC
PRG S&TECH INC
Resumen de: AU2023455061A1
The present invention relates to a use of a novel compound for preventing, alleviating, or treating Parkinson's disease, the novel compound exhibiting an effect of inhibiting synuclein aggregation in a Parkinson's disease (PD) mouse model. As a result of histological analysis, it was confirmed that the loss of dopaminergic neurons was blocked by treatment with the novel compound. Therefore, the novel compound can be effectively utilized in the development of a therapeutic agent for Parkinson's disease.
BOPI
Sede Electrónica
